more

Related Articles

Actavis to Buy Warner Chilcott To Expand in Women’s Health
Alliant, Bellisio Foods, TransDigm
Aridis Pharma Picks Up Kenta Biotech’s Anti-Infection Products
Bayer Buys Herbal Medicine Maker
Allcare Medical and Landauer Metropolitan Merge to Handle Medicare Changes

SLIDESHOW

The M&A Scene: CEO Leadership
Dealmakers gathered at the Harvard Club in New York on May 7 as part of ACG NY's CEO Leadership event. Peter Gonye, a co-leader within Spencer Stuart's private equity practice in North America was the keynote speaker. Panelists included M. Tatum Pursell, senior adviser, Unlimited Horizons; Tony Ecock, general partner, Welsh Carson Anderson & Stowe; Jim Follett, former CEO of Authentic Response Inc.; Doron Grosman, operating partner, Court Square Capital; and Joelle Marquis, partner, Arsenal Capital.

Watercooler

Far Cry from the Glory Days
These days, big buyers are more likely to co-invest with limited partners

Dealmakers

Time Inc. -Meredith Pairing Would Have Been Too Complicated, Says Jeff Bewkes in Keynote
The Time Warner chairman hints there may be a future deal for the spun-off magazine business, maybe even with Meredith

Columns

The Buyside:
Trench Dealfare
Strategic players in the aerospace and defense sector look to offset losses by remaining on the hunt for targets

Health Care
Valeant Acquires Targretin for $65M

Targretin is used to treat skin legions caused by cutaneous T-cell lymphoma

By ALLISON COLLINS
February 22, 2013

Montreal-based Valeant Pharmaceuticals International Inc. (NYSE: VRX) has acquired the U.S. rights to Targretin, medication used to treat skin problems, for $65 million.

The company bought the rights from Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co. Ltd, which is based in Japan. 

Targretin treats skin problems caused by cutaneous T-cell lymphoma, which can cause skin legions. The medication comes in pill and gel forms.

In September, Valeant agreed to buy Medicis Pharmaceutical Corp. (NYSE: MRX) for $2.6 billion. 

 

For more information on related topics, visit the following: